Clinical trials: Acute Myeloid Leukemia (AML) in Remission
Acute Myeloid Leukemia (AML) in Remission
ABC Maintenance Therapy for AML
Study Objectives: To evaluate the Relapse-Free Survival (RFS) and 1-year RFS rate in patients with Acute Myeloid Leukemia (AML) receiving maintenance therapy with Chidamide combined with Venetoclax and Azacitidine.
- Trial name
- ABC-Maint (NCT07521124)
- Testing
- Cohort 1 (MRD-Negative Patients): 61 subjects, Cohort 2 (MRD-Persistent Positive Patients): 43 subjects
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hematologic Malignancy, Acute Leukemia
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies.
- Conditions
- Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia
- Trial name
- NCT05735717
- Testing
- Fludarabine, Busulfan, Melphalan
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia (AML) in Remission
Phase IB/II of CPX-351 for Relapse Prevention in AML
This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR.
- Trial name
- NCT04990102
- Testing
- CPX-351
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Georgetown University
Acute Lymphoblastic Leukemia (ALL) in Complete Remission, Acute Myeloid Leukemia (AML) in Remission
Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients
This randomized clinical trial will evaluate two approaches of GvHD prophylaxis; the standard of care GVHD prophylaxis regimen (methotrexate/calcineurin inhibitors) and post-transplant cyclophosphamide with calcineurin inhibitors…
- Trial name
- PTCy-PMAT (NCT04314219)
- Testing
- Cyclophosphamide 50mg, Methotrexate
- Where
- Saudi Arabia
- Volunteers
- 264 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Acute Myeloid Leukemia (AML) in Remission, Stem Cell Transplantation
Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML
It is a randomized phase 3 study comparing two conditioning regimens in children with Acute Myeloid Leukemia, AML, undergoing allogenic stem cell transplantation.
- Trial name
- SCRIPT-AML (NCT05477589)
- Testing
- busulfan, cyclophosphamide and melphalan, BuCyMel, clofarabine, fludarabine and busulfan, CloFluBu
- Where
- 17 sites in Belgium, Denmark and 8 more
- Volunteers
- 170 people
- Sponsor
- Vastra Gotaland Region
Leukemia, Leukemia, Myeloid
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type
- Trial name
- CYNK001AML01 (NCT04310592)
- Testing
- CYNK-001
- Where
- 10 sites in United States
- Volunteers
- 27 people
- Sponsor
- Celularity Incorporated
Acute Myeloid Leukemia (AML) in Remission
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival (RFS) for younger adults with favorable-risk acute myeloid leukemia (AML) who…
- Trial name
- NCT05404906
- Testing
- Azacitidine, Venetoclax, Supportive care
- Where
- 2 sites in China
- Volunteers
- 124 people
- Sponsor
- The First Affiliated Hospital of Soochow University